Lexicon Pharmaceuticals recently gained FDA approval for its heart failure and type 2 diabetes drug, Inpefa, and is marketing the drug aggressively. Lexicon's financials show mixed results, with ...
Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback